# Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer

> **NCT01698918** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 202 (actual)

## Conditions studied

- Hormone Receptor Positive Breast Cancer

## Interventions

- **DRUG:** Everolimus
- **DRUG:** Letrozole
- **DRUG:** Exemestane
- **DRUG:** Alcohol-free dexamethasone mouth rinse (Stomatitis sub-study)
- **DRUG:** Standard of care to treat stomatitis (Stomatitis sub-study)

## Key facts

- **NCT ID:** NCT01698918
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-07
- **Primary completion:** 2015-12-17
- **Final completion:** 2021-01-13
- **Target enrollment:** 202 (ACTUAL)
- **Last updated:** 2023-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01698918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01698918, "Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01698918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*